Background: [Keytruda and Lenvima (Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor))] showed high clinical activity in PEMMELA cohort 1 in patients with pleural mesothelioma pre-treated with platinum-based chemotherapy. This study (cohort 2) aimed to investigate the clinical activity of this combination in … [Read more...]
Pembrolizumab Plus Lenvatinib as Second- and Third-Line Treatments of Pleural Mesothelioma
In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients with disease progression after … [Read more...]
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
Background: The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical studies in solid tumours. We assessed the clinical activity of this combination therapy [ of pembrolizumab plus lenvatinib ] in patients with pleural mesothelioma who … [Read more...]